1734P - Early impact of a personalized lung cancer interception program for heavy smokers

Background

Screening for lung cancer (LC) with Low-Dose Chest Computed Tomography (LDCT) reduces LC specific mortality. Interception-Lung is a French, soon to be nationally deployed, community-hospital and digital-physical personalized pilot LC screening and prevention program with an ultimate objective of reducing the incidence of advanced LC.

Methods

After physician (or self-) referral, men and women aged ≥ 50, active or former smokers (quit ≤ 10 years), are invited to attend a dedicated “One Stop Shop” that includes personalized prevention consultations, counselling on smoking cessation, lung cancer screening with LDCT on the basis of a shared medical decision in addition to educational group workshops on smoking, LC, nutrition and physical activity. As per the European position statement on LC screening recommendations, screening outcome is either positive, negative or indeterminate. A shared personalized prevention plan is handed to the participants and sent to their physicians. A follow-up visit is scheduled after each screening round.

Results

Between May 2021 and 2023, 276 persons (187 females, median age 57) attended the One Stop Shop. Fifty-four percent had post high school training or college education, 37% had a previous history of another cancer (mainly breast). Two hundred and two (73%) were active smokers, 15% had a regular cannabis consumption and 16% reported any use of vape. Median 6-year lung cancer risk as per the PLCOm2012noRace prediction model was 1.4% (0.7-2.9). Results of the first screening round were negative, indeterminate and positive in 65%, 31% and 4% of the participants, respectively. Five participants had surgery; 3 had lung cancer (stage 1 adenocarcinoma) and 2 a benign histology. The proportion of indeterminate screenings decreased from 31% to 8% at the second round. Out of 56 initially active smokers with already available extended follow-up data, 12 (21%) were abstinent at one year from the One Stop Shop.

Conclusions

A combined intervention mixing LC screening and prevention is feasible and could increase the benefit of LDCT screening and long-term smoking cessation rates. Reducing false-positives and improving risk-based identification and referral for screening is a major challenge.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Gustave Roussy.

Funding

Has not received any funding.

Disclosure

P. Abdayem: Non-Financial Interests, Institutional, Invited Speaker: AstraZeneca, MSD; Non-Financial Interests, Institutional, Principal Investigator: Cegedim-Santé. O. Mercier: Financial Interests, Personal, Advisory Board, Board on surgical oncology (lung cancer): AstraZeneca; Financial Interests, Personal, Advisory Board, Board for CTEPH (non-cancer related): MSD; Financial Interests, Institutional, Funding, Paceport Study investigator (non-cancer related) Study on pulmonary hemodynamics: Edwards Lifesciences. D. Planchard: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Samsung, Celgene, AbbVie, Daiichi Sankyo, Janssen, Seagen, Gilead, Pierre Fabre; Financial Interests, Personal, Invited Speaker: AstraZeneca, Novartis, Pfizer, priME Oncology, Peer CME, Samsung, AbbVie, Janssen; Non-Financial Interests, Principal Investigator, Institutional financial interests: AstraZeneca, BMS, Merck, Novartis, Pfizer, Roche, Daiichi Sankyo, Sanofi-Aventis, Pierre Fabre; Non-Financial Interests, Principal Investigator: AbbVie, Sanofi, Janssen. S. Delaloge: Financial Interests, Institutional, Advisory Board: AstraZeneca, Novartis, Pierre Fabre, Orion, Sanofi, Rappta, Cellectis, Isis/Servier; Financial Interests, Institutional, Invited Speaker: Exact Sciences, Pfizer, Seagen, Lilly, AstraZeneca, MSD; Financial Interests, Institutional, Advisory Board, ad board: Besins Healthcare; Financial Interests, Institutional, Invited Speaker, ESMO symposium: Gilead; Financial Interests, Institutional, Advisory Board, scientific board: Elsan; Financial Interests, Institutional, Steering Committee Member: Roche Genentech, BMS, Puma, AstraZeneca, Sanofi, Pfizer; Financial Interests, Institutional, Local PI: Orion; Financial Interests, Institutional, Funding: GE; Financial Interests, Institutional, Coordinating PI, clinical research funding to my institution: Taiho; Non-Financial Interests, Member of Board of Directors, Société Française de Sénologie et Pathologie Mammaire: SFSPM; Non-Financial Interests, Principal Investigator, H2020 funding: European Commission. All other authors have declared no conflicts of interest.